Dondov, Ganchimeg

Товч нэр

Dondov, Ganchimeg

Бүтэн нэр

Dondov Ganchimeg

Латин нэр

Dondov Ganchimeg

Албан тушаал

Судлаач

Харьяалал

Анагаахын Шинжлэх Ухааны Үндэсний Их Сургууль

ORCID

0000-0001-6314-6996

Scopus Author ID

57572273500

Now showing 1 - 5 of 5

Some of the metrics are blocked by your
consent settings
Diagnostic accuracy of serum pepsinogens for detecting chronic atrophic gastritis and gastric cancer: A meta-analysis
(2026-07-07)
Ganchimeg Dondov
;
Bayarmaa Nyamaa
;
Batbold Batsaikhan
;
Tegshjargal Badamjav
;
Sodnomtsogt Lkhagvasuren
Introduction: Recent studies have shown that serological biomarkers such as pepsinogens may facilitate the early detection of gastric cancer. Objective: This study aims to evaluate the diagnostic performance of serum pepsinogen I (PGI) and the PGI/pepsinogen II ratio (PGR) in detecting gastric cancer and chronic atrophic gastritis. Methods: A systematic literature search was conducted using MeSH terms related to atrophic gastritis, gastric neoplasms, pepsinogen A, sensitivity, and specificity. Twenty-one eligible studies were included in the quantitative synthesis. Results: For atrophic gastritis, the area under the curve was 0.74 (95% confidence interval [CI] = 0.70–0.77) for PGI and 0.78 (95% CI = 0.75–0.82) for PGR. The pooled sensitivity and specificity were 61.4% (95% CI = 48.2–73.2) and 86.4% (95% CI = 61.8–96.1), respectively, for PGI, and 72.4% (95% CI = 61.0–81.4) and 76.9% (95% CI = 49.5–91.9), respectively, for PGR. For gastric cancer detection, the area under the curve values were 0.76 (95% CI = 0.72–0.80) for PGI, 0.77 (95% CI = 0.73–0.80) for PGR, and 0.79 (95% CI = 0.75–0.83) for the combined PGI+PGR model. The pooled sensitivity and specificity were 69.8% (95% CI = 55.0–81.3) and 70.8% (95% CI = 58.7–80.6), respectively, for PGI, 76.2% (95% CI = 65.4–84.2) and 66.1% (95% CI = 56.1–74.8), respectively, for PGR, and 61.5% (95% CI = 50.9–72.1) and 86.7% (95% CI = 79.4–94.1), respectively, for PGI+PGR. Conclusion: Serum PGI and PGR can be used as an additional screening for high-risk subjects who may require gastroscopy or biopsy.
Some of the metrics are blocked by your
consent settings
Topical Meconium Improves Barrier Repair and Reduces Skin Inflammation in a Rat Model of Eczema
(2025-12-15)
Anudari Ichinkhorloo
;
Khuslen Batzorig
;
Ganchimeg Dondov
;
Batbold Batsaikhan
;
Tsend-Ayush Damba
Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by epidermal barrier dysfunction and immune dysregulation. While traditionally considered a waste product, meconium—the first stool of neonates—contains various bioactive compounds that may influence immune responses and epithelial integrity. This study investigates the dermatological effects of meconium in a chemically induced eczema model in Wistar rats, focusing on its potential to modulate inflammation and promote skin barrier repair. Meconium samples were collected from healthy neonates and applied topically to rats with Veet-induced eczema. The experimental groups included untreated eczema controls, meconium-treated rats, Meebo ointment-treated rats (positive control), and a healthy control group. Clinical assessments of erythema, ulceration, and edema were conducted, alongside histopathological evaluations of epidermal thickness and immune cell infiltration. Statistical analyses were performed using ANOVA with post-hoc Tukey tests. Meconium treatment significantly reduced erythema and ulceration scores compared to untreated eczema controls (p<0.01) and increased epidermal thickness (p<0.05). While less effective than Meebo ointment, meconium demonstrated notable anti-inflammatory and regenerative properties. The findings suggest that meconium contains bioactive components capable of modulating skin inflammation and enhancing barrier repair, warranting further investigation into its potential therapeutic applications in dermatological conditions.
Some of the metrics are blocked by your
consent settings
Topical Meconium Improves Barrier Repair and Reduces Skin Inflammation in a Rat Model of Eczema
(2025-12-30)
Anudari Ichinkhorloo
;
Khuslen Batzorig
;
Ganchimeg Dondov
;
Batbold Batsaikhan
;
Tsend-Ayush Damba
Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by epidermal barrier dysfunction and immune dysregulation. While traditionally considered a waste product, meconium—the first stool of neonates—contains various bioactive compounds that may influence immune responses and epithelial integrity. This study investigates the dermatological effects of meconium in a chemically induced eczema model in Wistar rats, focusing on its potential to modulate inflammation and promote skin barrier repair. Meconium samples were collected from healthy neonates and applied topically to rats with Veet-induced eczema. The experimental groups included untreated eczema controls, meconium-treated rats, Meebo ointment-treated rats (positive control), and a healthy control group. Clinical assessments of erythema, ulceration, and edema were conducted, alongside histopathological evaluations of epidermal thickness and immune cell infiltration. Statistical analyses were performed using ANOVA with post-hoc Tukey tests. Meconium treatment significantly reduced erythema and ulceration scores compared to untreated eczema controls (p<0.01) and increased epidermal thickness (p<0.05). While less effective than Meebo ointment, meconium demonstrated notable anti-inflammatory and regenerative properties. The findings suggest that meconium contains bioactive components capable of modulating skin inflammation and enhancing barrier repair, warranting further investigation into its potential therapeutic applications in dermatological conditions.
Some of the metrics are blocked by your
consent settings
Topical Meconium Improves Barrier Repair and Reduces Skin Inflammation in a Rat Model of Eczema
(2025-12-15)
Anudari Ichinkhorloo
;
Khuslen Batzorig
;
Ganchimeg Dondov
;
Batbold Batsaikhan
;
Tsend-Ayush Damba
Eczema, or atopic dermatitis, is a chronic inflammatory skin condition characterized by epidermal barrier dysfunction and immune dysregulation. While traditionally considered a waste product, meconium—the first stool of neonates—contains various bioactive compounds that may influence immune responses and epithelial integrity. This study investigates the dermatological effects of meconium in a chemically induced eczema model in Wistar rats, focusing on its potential to modulate inflammation and promote skin barrier repair. Meconium samples were collected from healthy neonates and applied topically to rats with Veet-induced eczema. The experimental groups included untreated eczema controls, meconium-treated rats, Meebo ointment-treated rats (positive control), and a healthy control group. Clinical assessments of erythema, ulceration, and edema were conducted, alongside histopathological evaluations of epidermal thickness and immune cell infiltration. Statistical analyses were performed using ANOVA with post-hoc Tukey tests. Meconium treatment significantly reduced erythema and ulceration scores compared to untreated eczema controls (p<0.01) and increased epidermal thickness (p<0.05). While less effective than Meebo ointment, meconium demonstrated notable anti-inflammatory and regenerative properties. The findings suggest that meconium contains bioactive components capable of modulating skin inflammation and enhancing barrier repair, warranting further investigation into its potential therapeutic applications in dermatological conditions.
Some of the metrics are blocked by your
consent settings
Risk Assessment of Gastric Cancer and Precancerous Condition Using Serum Pepsinogen and H. Pylori Antibody Test
(Mongolian National University of Medical Sciences, 2023-03-30)
Ganchimeg Dondov
;
Bayarmaa Nyamaa
;
Tegshjargal Badamjav
;
Batbold Batsaikhan
;
Erkhembulgan Purevdorj
Objectives: We aimed to determine serum PGs (serum pepsinogens) and H. Pylori IgG in atrophic gastritis and gastric cancer patients and evaluate the gastric cancer risk.Method: We enrolled 40 gastric cancer patients, 40 chronic atrophic gastritis patients and 40 healthy control subjects. Serum PGI, PGII, and H. pylori IgG levels were measured by ELISA. The PGI to PGII ratio was calculated.Results: The mean age of the subjects was 60±10.9 years, We found that 52.6% (n=60) were male. H. Pylori IgG was positive in 67 subjects. The serum PGI and PGR levels were significantly decreased in gastric cancer and atrophic gastritis groups compared to the healthy control. According to classification ABC (D), group D had higher proportion of atrophic gastritis cases, group C had higher proportion of gastric cancer cases than others. Additionally, we evaluated all subjects by giving one point to each of the age ≤40, positive family history of gastric cancer, positive previous gastric disease history, PGI ≤75.07 ng/ml, PGR ≤6.25, or two point to each of PGI ≤35.25 ng/ml, and PGR ≤5.27, with score ranging between 0-7. As score increased, the risk of atrophic gastritis or gastric cancer increased.Conclusion: A combination of methods involving PGs and other risk factors may predict the probability of gastric cancer and could identify individuals who may need upper endoscopy.

Dondov, Ganchimeg

Filters

Settings

Sort By

Results per page